Chinglin Lai, Ph.D.
Chief Executive Officer, Syncopation Consulting
Dr. Lai has over 25 years of industry experience in drug development across a broad range of therapeutic areas. His experience is primarily in first-in-human studies through late stage development for marketing approvals.
During his tenure at Alza Corporation (1994-2004), he contributed to the marketing approvals of 5 products in the US and EU and the in-licensing of 2 products. From 2004-2005, he worked at Intrabiotics Pharmaceuticals and was a member of a core team in evaluating in-licensing opportunities. From 2005 to 2016, Dr. Lai held leadership positions at Jazz Pharmaceuticals, overseeing biostatistics and data management functions. While at Jazz, Dr. Lai also provided advice to the evaluation of assets for potential acquisitions.
Dr. Lai is currently the CEO of Syncopation Consulting, Inc., which he co-founded in May 2016. Syncopation Consulting works with a network of experienced freelance statisticians and data analysts to provide consultation and services to the biopharmaceutical industry. Since May 2016, Dr. Lai and his team have provided consultation to 16 small-to-midsize biopharmaceutical companies and 1 investment fund.
Dr. Lai received his Ph.D. in Applied Statistics from the University of California, Riverside, with a concentration in experimental design.